Ulisun 100000IU Injection

Introduction

Ulisun is a medication containing the active ingredient Ulinastatin. It is available in injectable form and is used for various medical conditions.

Uses

Ulisun is prescribed for the treatment of inflammatory conditions and disorders associated with excessive inflammation. It is commonly used in the management of conditions such as acute pancreatitis, sepsis, and acute respiratory distress syndrome (ARDS).

Dosage and Administration

The dosage and administration of Ulisun should be determined by a healthcare professional based on the patient’s specific condition and medical history. It is usually administered intravenously or intramuscularly under medical supervision. The dosage may vary depending on the severity of the condition and the individual patient’s response to the medication.

Mechanism of Action

Ulinastatin, the active ingredient in Ulisun, works by inhibiting the activity of certain enzymes involved in the inflammatory response. It helps to reduce inflammation and prevent tissue damage associated with various inflammatory conditions.

Side Effects

Common side effects may include mild injection site reactions, such as redness, swelling, or pain. Serious side effects are rare but may include allergic reactions, severe skin rashes, or difficulty breathing. If any of these side effects occur, seek immediate medical attention.

Drug Interactions

inform your healthcare provider about all the medications you are currently taking, including prescription drugs, over-the-counter medications, and herbal supplements. Ulisun may interact with certain medications, including anticoagulants (blood thinners) or antiplatelet drugs, as it may increase the risk of bleeding. Discuss potential drug interactions with your healthcare provider before starting Ulisun.

Precautions

Before using Ulisun, inform your healthcare provider about any allergies you may have, especially to Ulinastatin or any other ingredients in the medication. Additionally, inform your healthcare provider about any other medical conditions you have, such as liver or kidney problems. Ulisun should be used with caution in pregnant or breastfeeding women, as the safety of the medication in these populations has not been established.

Storage

Ulisun should be stored in a cool and dry place, protected from light. It should be kept out of reach of children and pets. Do not use the medication if the packaging is damaged or if it has expired. Proper disposal methods should be followed as per local regulations.

Patient Tips

• Follow the instructions provided by your healthcare provider regarding the dosage and administration of Ulisun.
• If you experience any unusual or severe side effects, contact your healthcare provider immediately.
• Inform your healthcare provider about all the medications you are currently taking to avoid potential drug interactions.
• Store Ulisun properly and check the expiration date before use.
• Keep all appointments with your healthcare provider for regular monitoring and evaluation of your condition.
• If you have any questions or concerns about Ulisun, don’t hesitate to discuss them with your healthcare provider.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Han D, Shang W, Wang G, Sun L, Zhang Y, Wen H, Xu L. Ulinastatin- and thymosin alpha1-based immunomodulatory strategy for sepsis: A meta-analysis. Int Immunopharmacol. 2015 Dec;29(2):377-382. doi: 10.1016/j.intimp.2015.10.026. Epub 2015 Oct 27. [Accessed 8 Jun. 2024] Available at:
• Hong Y, Meng S, Wang S, Liu T, Liu J. Ulinastatin Alleviates Repetitive Ketamine Exposure-Evoked Cognitive Impairment in Adolescent Mice. Neural Plast. 2022 Dec 12;2022:6168284. doi: 10.1155/2022/6168284. eCollection 2022. [Accessed 0 Jun. 2024] Available at:
• Wei X, Zhu X, Jiang L, Long M, Du Y. Recent research progress on the role of ulinastatin in chronic kidney disease. Nephrology (Carlton). 2021 Sep;26(9):708-714. doi: 10.1111/nep.13906. Epub 2021 Jun 29. [Accessed 22 Jun. 2024] Available at:
• Li CZ, Qiang YY, Liu ZJ, Zheng LS, Peng LX, Mei Y, Meng DF, Wei WW, Chen DW, Xu L, Lang YH, Xie P, Peng XS, Wang MD, Guo LL, Shu DT, Ding LY, Lin ST, Luo FF, Wang J, Li SS, Huang BJ, Chen JD, Qian CN. Ulinastatin inhibits the metastasis of nasopharyngeal carcinoma by involving uPA/uPAR signaling. Drug Dev Res. 2023 Nov;84(7):1468-1481. doi: 10.1002/ddr.22098. Epub 2023 Aug 3. [Accessed 22 Jun. 2024] Available at: